CD63 and neoplasm: When investigating the association between overall survival and CD63+ tumor cell score, no significant correlation was found for patients with diffuse astrocytoma (p = 0.85), anaplastic astrocytomas (p = 0.31), or glioblastoma (p = 0.59).